Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (711-720 of 869) with videos related to

Pageof 87
Sort By:
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2012
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidenceMaria T Di Martino, Emanuela Leone, Nicola Amodio, et al.
Nature Medicine|May 13, 2014
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancersFrancesca Cottini, Teru Hideshima, Chunxiao Xu, et al.
Cancer Cell|September 15, 2012
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistanceDharminder Chauhan, Ze Tian, Benjamin Nicholson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Multiple myeloma. Clinical practice guidelines in oncologyKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Blood|December 18, 2012
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson, David Siegel, Rachid Baz, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseSonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, et al.
Cancer Research|March 21, 2020
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple MyelomaYi Hu, Huimin Liu, Chuanfeng Fang, et al.
Pageof 87

Showing results (711-720 of 869) with videos related to

Sort By:
Pageof 87
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2012
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidenceMaria T Di Martino, Emanuela Leone, Nicola Amodio, et al.
Nature Medicine|May 13, 2014
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancersFrancesca Cottini, Teru Hideshima, Chunxiao Xu, et al.
Cancer Cell|September 15, 2012
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistanceDharminder Chauhan, Ze Tian, Benjamin Nicholson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Multiple myeloma. Clinical practice guidelines in oncologyKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Blood|December 18, 2012
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson, David Siegel, Rachid Baz, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseSonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, et al.
Cancer Research|March 21, 2020
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple MyelomaYi Hu, Huimin Liu, Chuanfeng Fang, et al.
Pageof 87